Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag Distributing Luminex Assays in France

NEW YORK (GenomeWeb News) – French theranostics and IVD firm Theradiag will distribute Luminex's xTAG RVP and xTAG GPP assays in France, the companies said recently.

Luminex's xTAG RVP is a qualitative multiplex molecular diagnostic assay for the simultaneous detection of 19 viral types and subtypes from nasopharyngeal swabs, nasal aspirates, and bronchoalveolar lavages from individuals suffering from respiratory tract infections.

Meantime, the xTAG GPP identifies a variety of pathogens that cause gastroenteritis, and is the first molecular diagnostic kit covering over 90 percent of infections caused by bacteria, viruses, and parasites in a single test.

Further financial and other terms of the agreement were not disclosed.

Theradiag has been using Luminex’s multiplex technology to develop its own range of diagnostic kits for autoimmune diseases diagnosis since 1999.

"These new assays complement our growing portfolio of innovative IVD products using multiplex technology and strengthen our position in the expanding molecular diagnostic market," Theradiag CEO Michel Finance said in a statement.

In December, Luminex said that it would be moving to a direct sales channel for its molecular diagnostic products.

This story was updated from a previous version to provide additional information.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.